跳至主要内容
临床试验/ACTRN12612000635864
ACTRN12612000635864
已完成
2 期

Phase II of a novel telehealth-mediated nurse-led intervention to increase oral cancer therapy adherence amongst people with Chronic Myeloid Leukaemia (CML)(REMIND study)

Australasian Leukaemia and Lymphoma Group0 个研究点目标入组 40 人2012年6月14日

概览

阶段
2 期
干预措施
未指定
疾病 / 适应症
chronic myeloid leukaemia (CML)
发起方
Australasian Leukaemia and Lymphoma Group
入组人数
40
状态
已完成
最后更新
6年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2012年6月14日
结束日期
待定
最后更新
6年前
研究类型
Interventional
性别
All

研究者

发起方
Australasian Leukaemia and Lymphoma Group

入排标准

入选标准

  • 1\.a confirmed diagnosis of CML in the chronic phase with no signs and symptoms of progression to the accelerated or blastic phases as per investigator’s opinion
  • 2\.no evidence of Imatinib resistance (as determined by the site investigator)
  • 3\.Currently taking or about to commence treatment with Imatinib
  • 4\.over 18 years
  • 5\.proficient in English
  • 6\.able to give informed consent.
  • 7\.An ECOG performance status score of 2 or less at Screening

排除标准

  • 1\.Demonstrated cognitive or psychological difficulties that would preclude study participation as defined by the treatment team’s cognitive and / or psychiatric assessment or patient’s disclosed medical history
  • 2\.Too unwell to participate in the study as determined by the patient’s treatment team.

结局指标

主要结局

未指定

相似试验